Abstract 2485: A combined mregDC and Treg signature associates with antitumor efficacy of CCR4 antagonist tivumecirnon FLX475
Adam Grant(Rapt Therapeutics (United States)), George E. Katibah(Rapt Therapeutics (United States)), Molly Grandcolas(Rapt Therapeutics (United States)), Michael Chisamore(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jingtao Qiu(Shenzhen Genoimmune Medical Institute), Paul D. Kassner(Rapt Therapeutics (United States)), Denise de Almeida Nagata, Scott Jacobson(Rapt Therapeutics (United States)), Dirk G. Brockstedt(Rapt Therapeutics (United States)), Mohsen Sabouri Ghomi(Rapt Therapeutics (United States)), Rakesh K. Goyal(Rapt Therapeutics (United States)), William Ho(Baker Heart and Diabetes Institute), Marvin Au(Rapt Therapeutics (United States)), Shoji Ikeda(Rapt Therapeutics (United States)), Damian Trujillo(Aduro BioTech (United States)), Juraj Adamik(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 1
Related Papers
Multi-criteria decision making approaches for supplier evaluation and selection: A literature review
|European Journal of Operational Research|2009|2.2k
Supply chain risk management: a literature review
|International Journal of Production Research|2015|1.3k
Integrated analytic hierarchy process and its applications – A literature review
|European Journal of Operational Research|2007|1.2k
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
|Nature Medicine|1999|1.1k
The state-of-the-art integrations and applications of the analytic hierarchy process
|European Journal of Operational Research|2017|484